Gitnux/Report 2026

Tms Therapy Industry Statistics

The global transcranial magnetic stimulation system market reached $310.8 million in 2026, explore the tms therapy figures behind growth, companies and trends.
25Statistics
22Sources
6Sections
1Visuals
16mRead
Tms Therapy Industry Statistics
How this report is researched
01Editorial Scope

Before any source is gathered, an editor locks the question, what qualifies, and how the piece will be judged.

02Source Research

Search agents collect the source set and pull each data point out with its provenance attached.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 28 days

01 Industry overview

The tms therapy industry at a glance

The global transcranial magnetic stimulation system market is estimated at $310.8 million in 2026, with demand expanding as accelerated protocols, broader indications and outpatient mental-health care increase adoption.

$310.8M[6]
Global market size, 2026
9.7%[6]
Forecast CAGR, 2026–2033
57.2%[6]
North America share, 2025
79.8%[6]
Depression application share, 2025
Market size
The global transcranial magnetic stimulation system market was valued at $279.5 million in 2025 and is estimated at $310.8 million in 2026. The market definition covers TMS systems rather than the full value of clinical treatment services.[6]
Forecast & CAGR
Global market revenue is forecast to reach $594.5 million by 2033, representing a 9.7% compound annual growth rate from 2026 to 2033. Grand View Research identifies rising neurological and psychological disorder prevalence, technology development and product awareness as growth factors.[6]
Market share & regions
North America held 57.2% of global revenue in 2025, making it the leading region. Asia Pacific is identified as the fastest-growing regional market through 2033, while the report covers North America, Europe, Asia Pacific, Latin America and the Middle East and Africa.[6]
Segmentation
The market is segmented by type, application, age group and region. rTMS accounted for 66.5% of revenue in 2025, depression represented 79.8% of application revenue, and adults represented 95.5% of age-group revenue.[6]
Key players & concentration
The industry is moderately fragmented rather than dominated by a single supplier. Major and emerging participants include NeuroStar (Neuronetics), BrainsWay, MagVenture, Magstim, Nexstim, Neurosoft, eNeura, Soterix Medical and several Chinese manufacturers; four manufacturers held 61.7% of the 81 FDA TMS-treatment-system authorizations recorded through September 21, 2026, a regulatory measure that does not equal sales share.[6][1]
Pricing
Published U.S. self-pay prices in 2026 had a median of $7,472 for a standard course and $228 for a session, based on 17 and 20 clinic price lists respectively. Original Medicare allowed an average of $180.94 for a 2024 office follow-up session and paid $143.48, with state averages ranging from $103.34 to $217.46.[1]
Trends, drivers & challenges
Accelerated TMS is shortening treatment schedules: MagVenture received U.S. clearance in May 2026 for protocols delivering at least two sessions per day for adult major depressive disorder. Key challenges include the need for repeated clinic visits, uneven reimbursement and incomplete evidence on optimal targeting, combinations and long-term outcomes.[7][8][1]
Consumer behavior & competition
A typical conventional rTMS course involves daily sessions five days per week for four to six weeks, which favors providers able to offer convenient outpatient access and accelerated alternatives. Competition centers on clinical evidence, regulatory clearances, neuronavigation, software and provider training; the FDA recorded 81 TMS treatment-system authorizations from 2008 through September 21, 2026, with 13 in 2025.[8][1][6]
M&A
The most significant recent transaction was Neuronetics’ acquisition of Greenbrook TMS, completed on December 9, 2024, combining NeuroStar technology with Greenbrook’s network of 95 U.S. treatment clinics. BrainsWay also acquired a minority stake in Axis Integrated Mental Health in June 2025, extending strategic investment into clinic operations.[9][10]
Regulation
In the United States, TMS treatment systems are generally regulated as Class II devices through 510(k) clearance or the De Novo pathway. Medicare coverage policies require an FDA-approved device, documented medical necessity and progress monitoring; the CMS policy permits up to 20 visits over four weeks, followed by tapering visits, with additional treatment subject to response criteria.[11][12]
Latest news
In 2026, MagVenture received FDA clearance for accelerated TMS protocols for adult major depressive disorder, while Wave Neurosciences’ MeRT system received FDA clearance for PTSD in July. FDA records also show a new rTMS system authorization dated September 6, 2026, indicating continued expansion of device competition and clinical indications.[7][13][14]

02 Ranking

Top 9 Companies in the Tms Therapy Industry

The leading companies in the tms therapy industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 20, 2026 · Next review December 20, 2026

Verdict

BrainsWay stands out for Deep TMS systems because it commercializes Deep TMS systems for psychiatric disorders, while MagVenture focuses on non-invasive TMS treatment systems since it is a privately owned Danish manufacturer.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in TMS device

    BrainsWay

    IL

    Ranked #1 · 9.1 · TMS device manufacturers

    Why we picked it: It develops and commercializes Deep TMS systems for psychiatric disorders, supported by an 8.3% operating margin.

  2. Leader in TMS clinic

    neurocare group

    DE

    Ranked #4 · 8.7 · TMS clinic operators

    Why we picked it: It operates and supports TMS clinics across the US, Europe and Australia, tied to a clinical TMS platform.

  3. Leader in neuronavigation systems

    Rogue Research

    CA

    Ranked #5 · 8.5 · Neuronavigation systems

    Why we picked it: Its Brainsight navigation adoption in 1,500 laboratories positions it within neuronavigation and stimulation workflows.

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 9 companies in the tms therapy industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

BrainsWay

TMS device manufacturers · IL

9.1
2

MagVenture

TMS device manufacturers · DK

8.8
3

Nexstim

TMS device manufacturers · FI

8.8
4

neurocare group

TMS clinic operators · DE

8.7
5

Rogue Research

Neuronavigation systems · CA

8.5
6

Magnus Medical

Accelerated SAINT TMS therapy systems, United States · US

8.5
7

Soterix Medical

Clinical and research TMS and neuromodulation systems, US · US

8.4
8

DEYMED Diagnostic

TMS, EEG and EMG diagnostic systems, Czech Republic · CZ

8.4
9

Magstim

Clinical, research and navigated TMS systems, United Kingdom · GB

8.1

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 20, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 20). Top 9 companies in the tms therapy industry. In Tms Therapy Industry Statistics. Gitnux. https://gitnux.org/tms-therapy-industry-statistics/#top-companies

report visual · Comparison

Share of verified U.S. TMS clinics naming each device brand on their website

NeuroStar leads with 69.1%.

NeuroStar69.1%
BrainsWay13.1%
MagVenture11%
Magstim8.2%
Apollo2.4%
CloudTMS0.9%
source-verifiedtmsinstitute.com

04 Statistics

Market Intelligence

This section anchors demand and coverage levels, including 10,477 Original Medicare patients and 231,177 Original Medicare TMS sessions in 2024.

Market size and service revenue in the tms therapy industry

  • 10,477 Original Medicare patients received office-based TMS in the United States in 2024; the service category covers Medicare-billed office-based treatment.[1]
  • $180.94 was the average Medicare-allowed amount per TMS treatment session in the United States in 2024; the category covers office-based TMS therapy.[1]
  • 231,177 Original Medicare TMS sessions were billed by published clinicians in the United States in 2024; the category covers HCPCS 90868 treatment sessions.[1]

Firm counts and size structure in the tms therapy industry

  • 190 U.S. mental health treatment facilities offered transcranial magnetic stimulation in 2024; this broader facility population is the closest official aggregate covering TMS therapy providers.[2]
  • 196 multi-location groups held 51.5% of verified TMS clinic locations in the United States in September 2026; groups are defined by shared website domains.[1]
  • 1,779 verified TMS clinic locations operated in the United States in September 2026; the directory counts locations whose websites confirmed TMS, not all national clinics.[1]

Regional breakdown of the tms therapy industry

  • Utah had 12.8 verified TMS clinics per million residents in September 2026, the highest state rate; the denominator uses 2020 Census population.[1]
  • Florida accounted for 31.2% of U.S. Original Medicare TMS sessions in 2024, with 107,365 sessions; the category covers Medicare-billed TMS treatment.[1]
  • Mississippi had 0.7 verified TMS clinics per million residents in September 2026, the lowest state rate; the denominator uses 2020 Census population.[1]

05 Statistics

Operating Benchmarks

This section quantifies published Medicare billing and patient volume, including a median of 375 treatment sessions per clinician in 2024.

Operating metrics used in the tms therapy industry

  • The median published U.S. Medicare TMS clinician billed 375 treatment sessions in 2024, with the middle half billing 258–552 sessions; sessions use HCPCS 90868.[1]
  • The median published U.S. Medicare TMS clinician treated 16 patients in 2024, with the middle half treating 13–23 patients; publication requires at least 11 patients.[1]
  • 190 U.S. mental health treatment facilities offered TMS in 2024; SAMHSA defines the measure as facilities reporting transcranial magnetic stimulation among treatment approaches offered.[2]

06 Statistics

Clients & Demand

This section ties clinic directory presence to payer mix, including that 39.6% of verified locations listed Medicare in September 2026.

Service penetration and outsourcing in the tms therapy industry

  • 32.8 Original Medicare beneficiaries per 100,000 received TMS on an office-plus-facility basis in the United States in 2024; the denominator is Original Medicare beneficiaries.[1]
  • 39.6% of verified U.S. TMS clinic locations listed Medicare in September 2026, equal to 705 locations; the denominator is 1,779 verified locations.[1]
  • 38.2% of verified U.S. TMS clinic locations listed TRICARE in September 2026, equal to 679 locations; the denominator is 1,779 verified locations.[1]

07 Statistics

Delivery & Operations

This section reports supply-side coverage, including 1,779 verified TMS clinic locations operating across the United States as of September 29, 2026.

Delivery capacity and installed base in the tms therapy industry

  • 1,779 verified TMS clinic locations operated across the United States as of September 29, 2026; the directory count is a floor because unverified locations were excluded.[1]
  • 386 clinicians had a published Medicare CPT 90868 billing record for TMS in 2024, distributed across 254 U.S. cities.[1]
  • 289 U.S. mental-health facilities reported offering transcranial magnetic stimulation in the 2024 N-SUMHSS, equal to 2.1% of surveyed facilities.[2]

08 Statistics

Pricing

This section compares public pricing points, including a median $7,472 self-pay price for a standard course in 2026 and $228 per session.

Fees and price levels in the tms therapy industry

  • $300–$500 was the typical price range for one TMS therapy session in the United States in 2024, with patients commonly receiving 20–30 sessions.[3]
  • $1,530 was University of Colorado Medicine’s listed fee per TMS treatment-delivery and management session in Aurora, Colorado, in its 2025 fee schedule.[4]
  • $7,472 was the median published self-pay price for a standard TMS course in the United States in 2026, across 17 clinic price lists; the study defines TMS as conventional repetitive TMS or Deep TMS.[1]
  • $180.94 was the average Original Medicare allowed amount per office-based TMS treatment session in the United States in 2024, covering 331,935 sessions.[1]

09 Statistics

Risk & Compliance

This section documents payer policy constraints, including a five-minute maximum emergency-service response time under Blue Cross Blue Shield of Vermont’s 2025 policy.

Regulation and licensing in the tms therapy industry

  • Annual review was required for emergency-service relationships and mock drills under Blue Cross Blue Shield of Vermont’s 2025 TMS policy.[5]
  • Five minutes was the maximum emergency-service response time specified for facilities administering covered TMS under Blue Cross Blue Shield of Vermont’s 2025 policy.[5]
  • 18 years was the minimum patient age specified for covered TMS therapy under Blue Cross Blue Shield of Vermont’s 2025 policy.[5]

Key questions about the tms therapy industry

What is the 2026 market size for transcranial magnetic stimulation system revenue?
The global transcranial magnetic stimulation system market is estimated at $310.8 million in 2026.
How fast does the TMS system market grow between 2026 and 2033?
The forecast CAGR for 2026–2033 is 9.7%, taking global market revenue to a projected $594.5 million by 2033.
Which companies lead the tms therapy industry?
BrainsWay stands out for Deep TMS systems because it commercializes Deep TMS systems for psychiatric disorders, while MagVenture focuses on non-invasive TMS treatment systems since it is a privately owned Danish manufacturer.
What technology shift is affecting adoption of TMS protocols?
Accelerated TMS shortens treatment schedules and is tied to outpatient mental-health care adoption, with MagVenture receiving U.S. clearance in May 2026 for protocols delivering at least two sessions per day for adult major depressive disorder.
How fragmented is the TMS treatment-system authorization landscape in the United States?
The industry is moderately fragmented rather than dominated by a single supplier, and four manufacturers held 61.7% of the 81 FDA TMS-treatment-system authorizations recorded through September 21, 2026.
What does Medicare reimbursement look like for office-based TMS sessions?
Original Medicare allowed an average of $180.94 for a 2024 office follow-up session, with an average of $180.94 per TMS treatment session in the United States in 2024.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 20). Tms Therapy Industry Statistics. Gitnux. https://gitnux.org/tms-therapy-industry-statistics
MLA
Samuel Norberg. "Tms Therapy Industry Statistics." Gitnux, 20 Nov 2026, https://gitnux.org/tms-therapy-industry-statistics.
Chicago
Samuel Norberg. 2026. "Tms Therapy Industry Statistics." Gitnux. https://gitnux.org/tms-therapy-industry-statistics.